

Opto Circuits' subsidiary Eurocor GmbH launches international multi-center registry - Valentines Trial II

- **45 centers from 16 countries registered**
- **Study for treatment of de novo lesions with DIOR® DEB**

**Bonn, Germany | Bengaluru, India
February 15, 2011**

Eurocor GmbH, a wholly-owned subsidiary of Opto Circuits (India) Ltd., began the new global multi-center registry - Valentines Trial II on the occasion of Valentine's Day on 14th February 2011. Patients are being recruited from 45 centers around the globe until the beginning of CRT 2011 conference March, 1, 2011. The objective of the study is to evaluate the efficacy of DIOR® drug-eluting balloon in the treatment of de novo coronary artery lesions which don't need a stent.

"The primary objective of this multi-center, international registry is to assess clinical success and efficacy of the paclitaxel-eluting balloon treatment for de novo lesions at 6-9 months follow up", says Dr. Rembert Pogge von Strandmann, Director - Clinical Department, Eurocor GmbH.

Many patients enrolled in the trial are slated to undergo an angiographic follow-up to evaluate angiographic late lumen loss and binary restenosis rate after treatment with a paclitaxel-eluting balloon. The DIOR® balloon demonstrated efficacy in preclinical trials and effectiveness for the de novo lesions in small vessels and bifurcations as well as in in-stent restenosis applications in several clinical trials.

All data for analysis will be collected via an electronic data capture system and analyzed at the Cardiovascular Research Institute Data Coordinating Center of the Washington Hospital Center. Dr. Ron Waksman will be supported by three Principle investigators for the Study: Dr. Alfredo Rodriguez (Argentina), Dr. Antonio Serra (Spain) and Dr. Fazila Malik (Bangladesh).

The success of Valentines Trial I demonstrated Eurocor's inventiveness in engaging a global clinical population through a very unique trial. The final data of the Valentines Trial I which investigated DIOR® drug-eluting balloon treatment in in-stent restenosis will be announced Tuesday, March 1, 2011 at the CRT 2011 congress at 1:10 pm by Prof. Sigmund Silber, MD.